A b s t r a c t
A specific pathologic diagnosis is important in
The optimal care of patients with cancer requires a precise pathologic diagnosis. This is generally obtained through histologic examination of tumor tissue, often supplemented with the results of immunohistologic or other ancillary tests.
Obtaining an adequate biopsy sample sometimes requires an invasive surgical procedure, such as thoracotomy or laparotomy, which may be associated with considerable morbidity or expense. Therefore, increasing reliance has been placed on small biopsy samples obtained with a cutting needle, often under radiologic guidance.
Nowhere is the need for diagnostic precision greater than in the management of patients with malignant lymphoma. For example, the 3 most common lymphoma types, diffuse large Bcell lymphoma (DLBCL), follicular lymphoma, and Hodgkin lymphoma (HL), are associated with distinct biologic characteristics demanding tailored approaches to patient management. The pathologic diagnosis and classification of the numerous lymphoma types that are currently recognized involves the application of morphologic and immunophenotypic criteria, as outlined in the World Health Organization (WHO) system. 1 These criteria are based on relatively large tissue samples because the pathologic distinction between some hematolymphoid processes requires consideration of tissue architecture, a parameter that is difficult or impossible to assess in very small samples.
Several studies have evaluated the usefulness of needle core biopsy specimens obtained clinically in the diagnosis of lymphomas. They have found that the technique is well tolerated by patients, associated with a low rate of complications, and sufficient for clinical decision making in between 80% and 90% of cases. [2] [3] [4] [5] [6] [7] [8] [9] [10] Although a few such studies have considered the relative amenability of HL vs non-Hodgkin lymphoma (NHL) or high-vs low-grade lymphomas to diagnosis by cutting-needle biopsy, none have systematically evaluated the various specific types of NHL. 8, 11 Furthermore, most previous studies used lymphoma classification systems that antedate the current WHO scheme; this system incorporates morphologic and immunophenotypic criteria that are likely to affect the amenability of some lymphomas to accurate diagnosis in small specimens. Finally, most previous studies assessing the usefulness of the needle biopsy procedure defined a successful outcome according to the apparent sufficiency of the pathologic diagnosis for clinical decision making. Surprisingly, no study has systematically used the larger, excised sample from the same lesion as a "gold standard" to evaluate the accuracy of lymphoma classification based on very small tissue samples.
Tissue microarrays (TMAs) are constructed by arraying in a single recipient paraffin block small cores of tissue harvested from multiple donor blocks such that histologic sections prepared from the recipient block are representative of all of its constituent cores. Thus, TMAs permit efficient histopathologic and immunohistochemical evaluation of large numbers of small, formaldehyde-fixed, paraffin-embedded tissue specimens.
We used a TMA to evaluate the relative amenability of lymphomas of different types to accurate recognition based on small tissue samples. Diagnoses were made based on the examination of histologic and immunostained sections from a TMA representing 67 cases of malignant lymphoma and 17 cases of nonneoplastic lymphoid hyperplasia. The TMA core-based diagnoses were then correlated with those based on the original, larger samples.
Materials and Methods

Construction of a Randomized TMA
Paraffin-embedded lymphoma samples were identified by searching the laboratory information system of Kingston General Hospital, Kingston, Canada. The hematoxylin-phloxinsaffron (HPS)-stained and immunostained histologic slides from each case were retrieved and reviewed by 2 of us (P.L.F. and D.P.L.). Lymphomas were classified and (for follicular lymphomas) graded by consensus according to the WHO system. 1 All cases included in the study met the following criteria: adequate tumor representation in at least 1 paraffin block of formaldehyde-fixed tissue and unequivocal correspondence of the morphologic and immunophenotypic findings with the pathologic criteria used in lymphoma classification. The proportions of cases representing the various lymphoma types were selected so as to approximate the frequency with which they are encountered in North American practice.
Representative areas were marked on the glass slides for subsequent sampling in the TMA. The TMA was assembled using a tissue-arraying instrument (Beecher Instruments, Silver Spring, MD) as described previously. 12 Two 0.6-mm-diameter tissue cores were harvested from each case. The pairs of cores were arrayed in a recipient paraffin block in random order, as determined using a random number generator. Histologic sections were cut from the TMA block using a Leica microtome (Richmond Hill, Canada). The sections were mounted on adhesive glass slides (Surgipath Canada, Winnipeg, Canada), stained for HPS, and immunostained for CD45, CD20, CD3, CD5, CD10, CD15, CD21, CD30, CD79a, CD43, cyclin D1, CD23, bcl-2, bcl-6, terminal deoxynucleotidyl transferase, and Ki-67. Antibody sources, dilutions, and clones are shown in ❚Table 1❚. Antigen retrieval was performed by incubation of slides in EDTA for 30 minutes at 95°C in a kitchen steamer (T-Fal Canada, Scarborough, Canada). Immunohistochemical staining was done on a Ventana automated immunostainer (Ventana, Tucson, AZ) using the biotin-avidin immunoperoxidase technique. The signal was generated using a hydrogen peroxide-activated diaminobenzidine solution intensified with copper, and the sections were counterstained with hematoxylin. All antibody incubations were for 30 minutes at 37°C.
Diagnostic Evaluation
The HPS-stained and immunostained TMA sections were evaluated independently by 4 pathologists (P.L.F., D.J.B., B.F.B., and D.P.L.), all with expertise in lymph node pathology. Two of the pathologists had reviewed the original histologic slides retrieved from the archive; the others were told only that the samples were of lymphomas and nonneoplastic lymphoid tissues. Originally, 100 cases were retrieved; 16 cases were excluded from diagnostic evaluation, before scoring by the pathologists, because of inadequate (ie, <1 complete core) representation in the HPS-stained TMA section or, in 1 case, persistent uncertainly as to the lymphoma subtype based on review of the slides from the original large sample. Cores from the following cases were scored: B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), 7 cases; follicular lymphoma grade 1 or 2 (FL), 7 cases; marginal zone B-cell lymphoma (MZL), 10 cases; DLBCL, 8 cases; follicular lymphoma grade 3 (FL3), 3 cases; mantle cell lymphoma (MCL), 6 cases; classical HL, 14 cases; nodular lymphocyte predominance HL, 1 case; anaplastic large cell lymphoma, 1 case; peripheral T-cell lymphoma (PTL), 7 cases; precursor T-lymphoblastic leukemia/lymphoblastic lymphoma (TLL), 3 cases; and, reactive lymphoid hyperplasia (RL), 17 cases. For each case, the pathologists examined the HPS-stained and immunostained sections and recorded their favored diagnosis on a standard form along with a numeric score that reflected their level of confidence in their diagnosis (see the "Results" section for the definitions of these scores).
For each specimen, the TMA core-based diagnosis from each pathologist was compared with the excision diagnosis. The raw percentage of agreement and the standard unweighted κ scores were calculated after pooling the assessments from each of the 4 raters so as to create a combined sample of 336 (84 × 4) assessments. 13 Agreement is provided overall and by diagnosis. Comparison of the agreement among raters based on the 84 specimens, regardless of the gold standard diagnosis, was accomplished by calculating the multirater κ score.
Results
The performance of individual pathologists in making diagnoses based on the TMA cores that agreed with those based on the corresponding excised samples was reasonably consistent. The 4 pathologists made correct, specific diagnoses in 61, 62, 66, and 68 (73%-81%) of the 84 cases represented in the TMA. The rate of correct diagnosis was not significantly different between pathologists (P = .48). Moreover, the average concordance rate of the 2 pathologists who had made the gold standard diagnoses based on the excised samples was almost identical (<1% difference) to that of the 2 pathologists who had not seen the excised samples, suggesting that prior exposure to the larger samples provided little relative advantage.
In subsequent analysis, each pathologist-sample encounter was considered an independent data point. Thus, the results from 336 (ie, 84 samples × 4 pathologists) encounters were tabulated on 2-dimensional tables ❚Table 2❚ and ❚Table 3❚ in which the rows correspond to the gold standard diagnoses (excision diagnosis) and the columns to the diagnoses based on the TMA cores (TMA core diagnosis). Thus, concordant diagnoses fall on the diagonal across the first 11 diagnostic categories. Columns outnumber rows so as to accommodate additional, less specific designations applied by some pathologists to some of the TMA cores, a single encounter in which a diagnosis of sarcoma was made, and the encounters in which a pathologist was unable to make any diagnosis. Table 2 shows the pathologists' results overall. For each cell that falls on the diagonal across the first 11 rows and columns, the middle number (row percentage) corresponds to the sensitivity and the bottom number (column percentage) to the positive predictive power (ie, the portion of positive test results that are true positives) of the TMA core-based diagnosis relative to the gold standard, excision diagnosis.
Concordant, specific diagnoses (ie, those in which the diagnosis made based on the TMA cores corresponded exactly to the gold standard, shown in bold in the tables) were made in 76.5% of the encounters (257/336; κ = 0.73). Sometimes pathologists applied less specific diagnostic terms, including "DLBCL or grade 3 follicular lymphoma," "indolent-appearing B-cell lymphoma," and "lymphoma, not otherwise specified." Some cores were interpreted as "B-cell lymphoma, not otherwise specified"; these are included in the "lymphoma, not otherwise specified" column in the table. These less specific terms were applied correctly in the vast majority of cases (18/20) in which they were used. If the 18 correct core-based diagnoses are considered as concordant in the analysis, the overall concordance rate increases to 81.8% (275/336).
Three lymphoma types seem especially amenable to correct recognition in the small core samples: CLL, MCL, and TLL. These entities were recognized in the TMA cores with sensitivities ranging from 100% (12/12) for TLL to 86% (24/28) for CLL, and very high positive predictive powers of 100% for TLL (12/12) and CLL (24/24) and 95% (21/22) for MCL. In contrast, cases of FL, FL3, and MZL seemed relatively difficult to recognize in small samples. Among these cases the sensitivities of TMA core-based diagnoses ranged from 68% (19/28) for FL to 8% (1/12) for FL3, and positive predictive powers were 76% for MZL (16/21), 70% for FL (19/27), and 33% for FL3 (1/3). The pathologists achieved an intermediate level of performance in recognizing DLBCL, HL, PTL, and RL in the TMA cores. Among these categories, it is noteworthy that the positive predictive power for PTL, a diagnosis that can be difficult to make even based on large samples, was 100% (21/21).
The unweighted κ score is an alternative measure of agreement that corrects for agreement by chance. 13 The second to last row in Table 2 shows the κ scores calculated based on the agreement between the gold standard and TMA core-based samples for each diagnostic category. A value of 1 indicates perfect agreement between the methods, whereas a value of 0 represents no agreement beyond what would be expected by chance; negative values suggest agreement worse than expected by chance. The κ scores for CLL, MCL, and TLL are 1 or nearly 1, confirming a high rate of agreement with the gold standard diagnoses for these lymphoma types, whereas the lowest κ scores were obtained for FL, FL3, and MZL.
Provision of an unequivocal diagnosis in a pathology report implies a high degree of confidence on the part of the pathologist in the accuracy of his or her opinion. In difficult cases, pathologists typically include a statement expressing how confident they feel. The intent is to provide clinicians with an indication as to whether patients may safely be managed based on the interpretation provided or, alternatively, whether clinical decisions should be deferred pending the availability of additional information. This convention was modeled in our study by requiring the pathologists to accompany each of their TMA core-based diagnoses with a confidence score defined as follows: 3, confident opinion sufficient for planning patient management; 2, opinion may be sufficient for planning management, as determined by additional, perhaps clinical, considerations; 1, "suggestive" findings, definitely requiring more sampling or investigation to influence management decisions; and 0, no diagnosis. Not surprisingly, a strong correlation was evident between confidence score and the proportion of cases that were diagnosed correctly in the TMA: overall concordance between the core-based and gold standard diagnoses at confidence scores of 3, 2, and 1 were, respectively, 93.7% (136/145), 74.8% (77/103), and 57% (44/77); 11 cases were given a confidence level of 0.
TMA core-based diagnoses made at confidence scores 2 or 3 deserve particular attention because they might be expected to form the basis for clinical decision making. These results are given in Table 3 . All TMA core-based diagnoses that received a confidence score of 1 or 0 are accounted for in the "No Diagnosis" column. Of the TMA core-based diagnoses, ALCL, anaplastic large cell lymphoma; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; DLB/FL3, diffuse large B-cell lymphoma or follicular lymphoma grade 3/3; FL, follicular lymphoma grades 1/3 or 2/3; FL3, follicular lymphoma grade 3/3; HL, Hodgkin lymphoma; IBCL, indolent B-cell lymphoma; LNOS, lymphoma, not otherwise specified; MCL, mantle cell lymphoma; MZL, marginal zone B-cell lymphoma; NC, not calculated; No Dx, no diagnosis made; PTL, peripheral T-cell lymphoma; RL, reactive lymphoid hyperplasia; TLL, T-lymphoblastic lymphoma; TMA, tissue microarray. * For each diagnosis, the top number indicates the number of diagnoses given as that diagnosis, the middle number is the row percentage (ie, the number of diagnoses in the cell expressed as a percentage of the total number of "gold standard" diagnoses in the corresponding row), and the bottom number indicates the column percentage (ie, the number of diagnoses in the cell expressed as a percentage of the total number of TMA core diagnoses in the corresponding column). Bold type indicates concordant diagnoses. † Agreement between excision diagnosis and TMA core diagnosis. ‡ Agreement between raters' TMA core diagnoses. 248 (73.8%) were made with a confidence level of 3 or 2. Among these cases, the lymphomas could be distinguished from the nonneoplastic lymphoid infiltrates with a sensitivity of 96.6% (196 of 203 lymphoma cases were detected) and a specificity of 93% (42 of 45 lymphoid infiltrates recognized as nonneoplastic). RL was misdiagnosed as lymphoma (ie, falsepositives) in 3 cases (once each as FL, MZL, and DLBCL); all of these diagnoses were associated with confidence scores of 2 (implying less than complete confidence on the part of the pathologists). The 7 false-negative diagnoses (ie, lymphomas misinterpreted as RL) included 4 cases of MZL and 1 case each of CLL, FL, and HL.
Restricting the analysis to TMA core-based diagnoses made with confidence scores of at least 2 is expected to increase the positive predictive power at a cost of reduced sensitivity. The results shown in Table 3 indicate that this is generally what occurred. However, it is noteworthy that for the lymphoma types associated with the highest concordance rates, CLL, MCL, and TLL, almost all of the correct diagnoses (1 case of MCL was the exception) were made with a confidence score of at least 2, indicating that these lymphoma types are generally recognized with an especially high degree of confidence. Although confident TMA core-based diagnoses of HL and PTL were made with relatively low sensitivity (73% [44/60] and 57% [16/28], respectively), both were associated with high positive predictive power (94% [44/47] and 100% [16/16], respectively), indicating that these diagnoses were reasonably reliable once made. Confident TMA core-based diagnoses of DLBCL were associated with reasonably high sensitivity (88%) but, importantly, modest positive predictive power (85%) resulting from misapplication of the diagnosis to cases of MCL, MZL, PTL, and RL. Confident, TMA core-based ❚Table 3❚ Concordance at Confidence Scores of 2 or 3 * diagnoses of FL, FL3, MZL, and RL were associated with low sensitivity (8%-62%) and low to modest positive predictive power (50%-86%).
The relative amenability of different lymphoma types to accurate diagnosis in small samples may also be evaluated based on the interobserver agreement achieved when several pathologists review the same TMA sample. Because this measure does not rely on reference to an external standard (in this case, the gold standard diagnosis based on the large, excised sample), it complements our other results. Multirater κ scores representing the agreement between the pathologists' TMA core-based diagnoses are shown in the last row of Table 2 . They show that interobserver agreement was greatest for CLL, MCL, and TLL; lowest for FL, FL3, and MZL; and intermediate for DLBCL, HL, PTL, and RL. Therefore, these relative rates of interobserver agreement seem to correspond to the relative amenability of these lymphoma types for accurate recognition in small samples.
Slides were reviewed from cases in which erroneous diagnoses were associated with high confidence scores to determine why potentially distinctive immunophenotypic profiles failed to result in accurate diagnosis. CD10, bcl-6, and bcl-2 are expressed in most cases of FL and may be expected to assist in their recognition. However, CD10 and bcl-6 are also expressed in cases of DLBCL and in nonneoplastic lymphoid follicles, and the diagnostic significance of bcl-2 expression is largely limited to cases in which it occurs within recognizable follicle centers. Thus, several diagnostic errors in our study seemed to have been related to the difficulty of correlating expression of these markers with the tissue architecture in very small specimens. Both cases of MZL that were misdiagnosed as HL were associated with large, B-lineage immunoblasts or centroblasts that expressed CD30; these seem to have been misinterpreted as Hodgkin cells. Taking careful note of the lineage of the predominant, small cell lymphoid infiltrate when interpreting the CD30 staining in putative Hodgkin cells would seem potentially helpful in avoiding this pitfall because background T cells are likely to predominate in classical HL, whereas B cells will generally predominate in most B-lineage NHLs. Misdiagnosis of cases of PTL as DLBCL seemed to have resulted from interpreting the B cells in the sample, which are often quite abundant and may be cytologically alarming, as the neoplastic component.
Discussion
Because we, as pathologists, are asked rather frequently to make lymphoma diagnoses based on small specimens obtained using cutting needles, we have been dismayed by the relative dearth of objective data available to guide this practice. The usefulness of the needle biopsy technique is influenced by several parameters, some of which cannot be studied by using a TMA core-based modeling approach such as ours. For example, beyond such strictly clinical issues as patient morbidity, clinically obtained needle biopsy specimens may be associated with an increased risk of sampling error or crush artifact. Conversely, the practice of sending one or more cores for analysis by flow cytometry may improve the accuracy of the technique as used in the clinical setting. However, considering the fundamental importance of tissue architecture in the conventional pathologic diagnosis and classification of lymphomas and the demonstrated importance of sample size in determining diagnostic success among clinically obtained needle biopsy specimens, it is clear that sample size is the single most important parameter distinguishing needle biopsy specimens from excised samples, at least from the pathologist's viewpoint. 14 Each of our TMA cores had a cross-sectional area of 0.3 mm 2 such that 0.3 to 0.6 mm 2 (ie, from 1 or 2 cores) was available for histologic examination from each case. In our experience, the size of the cutting needle biopsy specimens obtained clinically varies widely such that most (although by no means all) are larger than our TMA cores. In this respect, caution is required in applying our results to clinical practice. For example, whereas only 73.8% of our TMA core-based diagnoses were made confidently, this proportion is likely to be higher in a set of clinical specimens that includes larger samples. Small samples are likely to be especially problematic in dealing with lymphoid processes, such as HL or PTL, in which cellular heterogeneity impedes recognition of key cellular subpopulations, and in distinguishing between the various lymphomas of follicle center cell origin, including FL, FL3, and DLBCL, in which tissue architecture is of cardinal importance. These caveats are offset by, and largely inseparable from, the opportunity provided by our modeling approach to maintain a measure of control over the critical size variable, maintaining it conservatively toward the lower extreme of what might be considered acceptable in a clinical specimen, to more effectively isolate the potentially important variable of lymphoma subtype in determining diagnostic success in small samples.
We found that CLL, MCL, and TLL were diagnosed with particularly high sensitivity, positive predictive power, interobserver reproducibility, and confidence in the small samples. These are "small cell" lymphomas that may be morphologically similar to one another; however, their immunophenotypic profiles are distinctive. In contrast, FL, FL3, and MZL, lymphomas that also generally contain a small cell component but lack distinctive immunophenotypes discernible using commonly available antibodies, were difficult to diagnose. These observations support the notion that pathologists place especially heavy reliance on immunophenotypic and cytologic data when faced with very small specimens. It follows that diagnostic accuracy in such specimens will be heavily influenced by the relative amenability of lymphoma subtypes to diagnosis based on immunologic criteria and that the identification of new diagnostic antibodies useful in the specific recognition of lymphoma types that are difficult to recognize in small samples is highly desirable. Furthermore, the routine application of a broad panel of immunostains, relative to the more tailored panels generally applied to larger specimens, seems justified when dealing with small specimens in which limited appreciation of tissue architecture is likely to impede the generation of morphologically based diagnostic hypotheses.
Fluorescence in situ hybridization (FISH) is applicable to small samples of paraffin-embedded tissue and useful in detecting cytogenetic abnormalities that correlate with lymphoma subtype. For example, FISH-based assays are available for chromosomal translocations associated with follicle center cell-derived lymphomas, MCL and MZL. 15 Although it was beyond the scope of our study, a TMA core-based approach similar to ours might be useful for evaluating the relative potential of various combinations of FISH probes to complement immunostains in the classification of small lymphoma samples.
The results shown in Table 3 include several confident but erroneous diagnoses based on the small samples that, in a clinical setting, might have been expected to contribute to inappropriate clinical management, including several cases in which RL was misdiagnosed as lymphoma (ie, confident false-positives). We infer that reliance on very small samples for the definitive pathologic diagnosis of lymphoma is associated with a greater risk of diagnostic error than that associated with larger samples. Although aspects of our modeling approach prevent us from quantifying this risk precisely, it is nevertheless apparent that exclusive reliance on needle biopsy specimens for clinical decision making in a given case of lymphoma should be justified by a reasonable expectation that the benefit to the patient outweighs the risk of diagnostic error. In documenting the relative amenability of different lymphoma types to accurate diagnosis in small tissue samples, we believe that our work will also be useful in informing clinical practice in more specific ways. For example, our results provide objective guidance for pathologists in assessing the relative reliability of the specific lymphoma diagnoses that they make based on small samples and for clinicians in considering which of their patients with previously diagnosed lymphomas may most reliably be monitored using cutting needle biopsies.
